Navigation Links
Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
Date:11/8/2011

in-stent late lumen loss of 0.03 mm at four months, 0.10 mm at six months and 0.08 mm at eight months follow-up with no binary restenosis or revascularizations. The mean in-stent late lumen loss values at four, six and eight months were 0.01, 0.21 and 0.09 mm, respectively. The mean and median values were comparable except at the six month time point, in which one patient experienced a high late loss value due to treatment of a highly calcified lesion and under-expansion of the stent. When data from this patient is excluded, the six month mean LLL is 0.10 mm. The median percent of stent struts covered by tissue was 96% at eight months, 97% at six months and 90% at four months per OCT analysis. IVUS confirmed good inhibition of neointimal hyperplasia. A MACE rate of 6.7%, including two non-Q wave myocardial infarctions (MI), one peri-procedural and one non-target vessel MI, was reported through eight months follow-up.

"The MiStent DES was designed to address a need for improved patient safety while providing equivalent or better efficacy as compared to currently available drug eluting stents," observed Dennis Donohoe, M.D., Chief Medical Advisor to Micell. "The excellent clinical outcomes of the DESSOLVE I trial demonstrate the value of the MiStent design in enabling elimination of drug and polymer from the stent in 45 to 60 days and providing patients the best of DES and BMS in one solution."

About DESSOLVE I and DESSOLVE II Studies

The DESSOLVE I trial, the first clinical assessment of safety and efficacy of the MiStent DES, treated thirty patients with de novo lesions in coronary arteries ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm length stent. Subjects were enrolled across five study centers in New Zealand, Australia and Belgium. Three independent subgroups of 10 patients each were evaluated using angiography, IVUS and OCT at three time points: four, six and eight months. The pr
'/>"/>

SOURCE Micell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micell Technologies Announces Presentation of Clinical Data at TCT 2011
2. Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent® Drug-Eluting Coronary Stent
3. Micell Technologies Announces Reduced Clinical Trial Sample Size for MiStent® Drug-Eluting Coronary Stent Based on Early Clinical Data
4. Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
5. BioMarCare Technologies Ltd. Granted Access to Archived Samples in the Hadassah Medical Center
6. Medisafe 1 Technologies Pre-pays Additional 2 Convertible Promissory Notes Due in Full to Avoid Dilution to Shareholders
7. Filtrona Porous Technologies to Introduce New Hydrophilic Foam Products for Advanced Wound Care at the MEDICA / COMPAMED Trade Fair
8. China Medical Technologies to Announce Results for the Second Fiscal Quarter Ended September 30, 2011 on November 18, 2011
9. AquaLiv Technologies Subsidiary AquaLiv, Inc. Discusses Registration In Kenya Concerning Its HIV/AIDS Treatment
10. The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion
11. Connectyx Technologies to Host Teleconference on Third Quarter Financial Results on Tuesday November 15, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... UPI ), a medical device company that ... voiding dysfunctions, today reported financial results for the fiscal ... revenue for the Company,s Urgent ®  PC Neuromodulation System ... record, as compared to $3.9 million in the third ...
(Date:1/22/2015)... Jan. 22, 2015  Bio-Techne Corporation (NASDAQ: TECH ... first member of the new Simple Plex platform through ... launch represents the re-branding of the previously acquired CyPlex ... platform is a transformative immunoassay technology which integrates an ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Microbiology Testing/Clinical Microbiology ... - Global Forecast to 2019" report to ... a wide array of techniques for the detection ...
Breaking Medicine Technology:Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... Misonix, Inc. (Nasdaq: MSON ), a ... innovative therapeutic ultrasonic products worldwide for wound debridement, ... and medical applications, announced today that Michael A. ... Richard Zaremba, Chief Financial Officer, are scheduled to ...
... Jan. 3, 2011 Clinicians may soon have a new ... (HSV) – one of the most common sexually transmitted infections ... Dickinson and Company) (NYSE: BDX ), announced today ... 510(k) clearance for the first fully automated molecular tests to ...
Cached Medicine Technology:Misonix to Present at Sidoti & Company 2011 Micro Cap Conference 2New Amplified Molecular Tests Promise to Help Improve Diagnosis and Treatment of Herpes Patients 2
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce ... ever created for kids with cancer. The Chemo Duck App, available ... filled with enjoyable games to help children of all ages living ... helps to keep kids entertained, educated and at ease while waiting ...
(Date:1/22/2015)... is a seasoned and trusted leader who consistently delivers trendy ... have it lead the wedding dress industry into the future. ... for the global market. , “The CEO of VogueQueen is ... on continuing the goal of operational excellence and giving back ...
(Date:1/22/2015)... January 23, 2015 Angelweddingdress is a famous ... invites its customers to follow it on Facebook, Twitter, and ... Valentine’s Day gift. Angelweddingdress draws a lottery every week. , ... to Feb. 28, 2015. Click Angelweddingdress homepage for ...
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3
... Products and Pipeline to Enhance Galderma,s Position in ... 26 ,Galderma Pharma S.A., a global specialty pharmaceutical ... CGPI ) today,announced a definitive agreement pursuant ... will acquire all of the outstanding,shares of CollaGenex ...
... published by the European Society of Cardiology1 and the ... in cardiovascular disease across Europe. One fact, nevertheless, ... cause of death in the European Union, killing over ... economy over 192 billion Euros annually. Many of ...
... VIEJO, Calif., Feb. 25 The Ensign,Group, ... company of the Ensign(TM) group of,skilled nursing, ... that GE Healthcare Financial Services has expanded,Ensign,s ... it an,additional five years., (Logo: ...
... for Patient Safety Legislation Essential to Reduce ... ST. PAUL, Minn., Feb. 25 The ... be addressed with legislation,advanced by the Minnesota ... will champion "Staffing For Patient Safety" legislation,that ...
... Blunt (Mo.) issued the following statement today regarding ... Leader John,Boehner (Ohio) and Democratic Leader Steny Hoyer ... path to economic stability:, "This legislation makes ... path to long-term economic stability. Without attention by,2017, ...
... First Therapeutic Community,Program in the National Registry of ... 25 The Phoenix Academy,Therapeutic Community (TC) model ... community program for adolescents to be listed,in the ... by United States Department of Health and Human ...
Cached Medicine News:Health News:Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals 2Health News:Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals 3Health News:Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals 4Health News:Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals 5Health News:Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals 6Health News:The human and economic cost of heart disease in Europe 2Health News:The human and economic cost of heart disease in Europe 3Health News:The Ensign Group Establishes $50 Million Credit Facility with GE Healthcare Financial Services 2Health News:Minnesota Registered Nurses Promote Law to Improve Patient Care and Address Health Care Costs 2Health News:Minnesota Registered Nurses Promote Law to Improve Patient Care and Address Health Care Costs 3Health News:Minnesota Registered Nurses Promote Law to Improve Patient Care and Address Health Care Costs 4Health News:Phoenix Academy's Therapeutic Community Model Is First to be Federally Recognized as Evidence-Based 2
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
McPherson curved tying forceps is long has curved shafts with tying platform 4 mm, serrated handle and polished finish. Overall length 110 mm....
McPherson straight tying forceps have straight shafts, tying platforms 4 mm, serrated handle, polished finish, overall length 85 mm....
Suture tying forceps (S&T) is straight, 13.5 cm long, flat handle, 9 mm wide, tip diameter 0.3 mm with tying platform....
Medicine Products: